Metaclipse Therapeutics is a leading biotechnology company based in Atlanta, GA, specializing in the development of membrane-bound biological adjuvants for the treatment of cancer and infectious diseases. Their innovative science focuses on developing next-generation immunotherapies, including personalized vaccine immunotherapy platforms, to activate the immune system and eliminate cancer cells. Additionally, Metaclipse is dedicated to creating vaccine platforms for infectious disease prevention, with a particular emphasis on providing superior protection for the elderly and immune-compromised individuals. With a proprietary technology platform that combines particulate antigen formulations with membrane-linked cytokine and immunostimulatory protein adjuvants, Metaclipse aims to deliver breakthrough therapies that stimulate specific immune pathways and achieve desired immune responses. Their lead product platform, Membrex, shows remarkable potential in preclinical cancer models and is expected to enter first-in-human Phase 1 clinical trials for advanced triple negative breast cancer and head and neck squamous cell carcinoma in early 2024. Metaclipse intends to commercialize its products through licensing agreements with major pharmaceutical companies, once safety and effectiveness have been established.Generated from the website